Imaging the Nucleus Accumbens in Major Depressed Patients 'Treated With Pramipexole
Status:
Terminated
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
We hope to learn how a brain circuit that is important to the understanding of depression,
anhedonia and positive affect responds to a novel pharmaceutical treatment for depression and
related symptoms. Adults who have a diagnosis of major depression and are not completely
responsive to antidepressant medication will be sought out for participation; as will an
equal number of adults not suffering from the disorder. Those suffering from depression will
be given pramipexole, an investigational medication for eight weeks during which information
will be collected about mood, cognition, and brain function. Adults not suffering from
depression will also be evaluated with these measures.
Phase:
Phase 4
Details
Lead Sponsor:
Stanford University
Collaborator:
National Alliance for Research on Schizophrenia and Depression